These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8639883)

  • 1. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma.
    Osterborg A; Boogaerts MA; Cimino R; Essers U; Holowiecki J; Juliusson G; Jäger G; Najman A; Peest D
    Blood; 1996 Apr; 87(7):2675-82. PubMed ID: 8639883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.
    Cazzola M; Messinger D; Battistel V; Bron D; Cimino R; Enller-Ziegler L; Essers U; Greil R; Grossi A; Jäger G; LeMevel A; Najman A; Silingardi V; Spriano M; van Hoof A; Ehmer B
    Blood; 1995 Dec; 86(12):4446-53. PubMed ID: 8541533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.
    Osterborg A; Brandberg Y; Molostova V; Iosava G; Abdulkadyrov K; Hedenus M; Messinger D;
    J Clin Oncol; 2002 May; 20(10):2486-94. PubMed ID: 12011126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population.
    Yang S; Jun M; Hong-Li Z; Jian-Min W; Chun W; Lu-Gui Q; Yong-Qiang Z; Jun Z; Jian H; Zhi-Xiang S
    Int J Hematol; 2008 Sep; 88(2):139-144. PubMed ID: 18629603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-standing resolution of anemia in symptomatic low-grade non-Hodgkin's lymphoma patients treated with recombinant human erythropoietin as sole therapy.
    Samuelsson J
    Med Oncol; 2002; 19(1):69-72. PubMed ID: 12025893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production.
    Cazzola M; Beguin Y; Kloczko J; Spicka I; Coiffier B
    Br J Haematol; 2003 Aug; 122(3):386-93. PubMed ID: 12877665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy.
    ten Bokkel Huinink WW; de Swart CA; van Toorn DW; Morack G; Breed WP; Hillen HF; van der Hoeven JJ; Reed NS; Fairlamb DJ; Chan SY; Godfrey KA; Kristensen GB; van Tinteren H; Ehmer B
    Med Oncol; 1998 Sep; 15(3):174-82. PubMed ID: 9819794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma.
    Baz R; Walker E; Choueiri TK; Abou Jawde R; Brand C; McGowan B; Yiannaki E; Andresen S; Hussein MA
    Acta Haematol; 2007; 117(3):162-7. PubMed ID: 17148935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma.
    San Miguel JF; García-Sanz R
    Med Oncol; 1998 Aug; 15 Suppl 1():S29-34. PubMed ID: 9785334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
    Garton JP; Gertz MA; Witzig TE; Greipp PR; Lust JA; Schroeder G; Kyle RA
    Arch Intern Med; 1995 Oct; 155(19):2069-74. PubMed ID: 7575066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin in the treatment of cancer-related anaemia.
    Kasper C; Terhaar A; Fosså A; Welt A; Seeber S; Nowrousian MR
    Eur J Haematol; 1997 Apr; 58(4):251-6. PubMed ID: 9186536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation.
    Baron F; Sautois B; Baudoux E; Matus G; Fillet G; Beguin Y
    Exp Hematol; 2002 Jun; 30(6):546-54. PubMed ID: 12063021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
    Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
    Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
    Abdelrazik N; Fouda M
    Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial.
    Glossmann JP; Engert A; Wassmer G; Flechtner H; Ko Y; Rudolph C; Metzner B; Dörken B; Wiedenmann S; Diehl V; Josting A
    Ann Hematol; 2003 Aug; 82(8):469-475. PubMed ID: 12910374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy.
    Dmoszynska A; Kloczko J; Rokicka M; Hellmann A; Spicka I; Eid JE
    Haematologica; 2007 Apr; 92(4):493-501. PubMed ID: 17488660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study.
    Faller B; Slingeneyer A; Waller M; Michel C; Grützmacher P; Müller HP; Barany P; Grabensee B; Issad B; Schmitt H
    Clin Nephrol; 1993 Sep; 40(3):168-75. PubMed ID: 8403573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis.
    Bárány P; Clyne N; Hylander B; Johansson AC; Simonsen O; Larsson R; Frisenette-Fich C; Svensson B; Helmers C
    Perit Dial Int; 1995; 15(1):54-60. PubMed ID: 7734561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations.
    Kampf D; Eckardt KU; Fischer HC; Schmalisch C; Ehmer B; Schostak M
    Nephron; 1992; 61(4):393-8. PubMed ID: 1501734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.